Ginkgo Bioworks Holdings Inc (DNA)
8.10
+0.40
(+5.19%)
USD |
NYSE |
Sep 27, 16:00
8.10
0.00 (0.00%)
After-Hours: 18:38
Ginkgo Bioworks Holdings Cash from Investing (Quarterly): -26.84M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -26.84M |
March 31, 2024 | -12.11M |
December 31, 2023 | -46.67M |
September 30, 2023 | -3.381M |
June 30, 2023 | -11.22M |
March 31, 2023 | -19.41M |
December 31, 2022 | 29.74M |
Date | Value |
---|---|
September 30, 2022 | -46.49M |
June 30, 2022 | -14.66M |
March 31, 2022 | -35.98M |
December 31, 2021 | 4.228M |
September 30, 2021 | -30.51M |
June 30, 2021 | -23.93M |
March 31, 2021 | -23.05M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-46.67M
Minimum
Dec 2023
29.74M
Maximum
Dec 2022
-18.59M
Average
-21.23M
Median
Cash from Investing (Quarterly) Benchmarks
UnitedHealth Group Inc | -7.417B |
Pacific Biosciences of California Inc | 76.84M |
Natera Inc | -32.05M |
10x Genomics Inc | 11.95M |
Verve Therapeutics Inc | 30.15M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -84.39M |
Cash from Financing (Quarterly) | -0.226M |
Free Cash Flow | -346.60M |
Free Cash Flow Per Share (Quarterly) | -2.169 |
Free Cash Flow to Equity (Quarterly) | -111.42M |
Free Cash Flow to Firm (Quarterly) | -111.42M |
Free Cash Flow Yield | -85.70% |